Raymond James Financial’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-677
Closed -$7.9K – 5644
2026
Q2
$7.9K Hold
677
– – ﹤0.01% 5377
2026
Q1
$11K Hold
677
– – ﹤0.01% 5247
2025
Q4
$16.1K Hold
677
– – ﹤0.01% 5106
2025
Q3
$21.1K Sell
677
-168
-20% -$5.3K ﹤0.01% 4898
2025
Q2
$16.5K Hold
845
– – ﹤0.01% 5684
2025
Q1
$14.5K Sell
845
-33
-4% -$781 ﹤0.01% 4749
2024
Q4
$23.2K Buy
+878
New +$35.2K ﹤0.01% 4711

Other funds holding TRIB

Raymond James Financial's TRIB Position: Q3 2026 in Review

Raymond James Financial sold out of Trinity Biotech (TRIB) in Q3 2026, closing a stake of 677 shares — an estimated $7.9K sold.

Raymond James Financial first reported a position in TRIB in Q4 2024 and held it in 7 quarters. The position peaked at $23.2K in Q4 2024. 10 funds tracked by Wall St. Rank hold TRIB as of Q3 2026.

  • Raymond James Financial reported no remaining Trinity Biotech position as of Q3 2026 after selling out during the quarter.
  • Raymond James Financial sold 677 Trinity Biotech shares in Q3 2026, an estimated $7.9K.
  • Raymond James Financial first reported a position in Trinity Biotech in Q4 2024 and held it in 7 quarters.
  • Raymond James Financial's Trinity Biotech position peaked at $23.2K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.